[A20-46] Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Last updated 17.08.2020

Project no.:
A20-46

Commission:
Commission awarded on 15.05.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Patients with high-risk non-metastatic castration-resistant prostate cancer

Result of dossier assessment:

Disadvantages in some side effects do not question advantages particularly in overall survival; hint of considerable added benefit.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form